Targeting two overexpressed receptors, for instance CTLA-4 and OX40, in the tumor has the potential to increase the localization of BsAbs to the tumor site compared to monospecific antibodies, which may reduce the risk of systemic T cell activation and improve efficacy. Here, CTLA4 is linked to neoplasm.